GALAPAGOS NV-SPON ADR (GLPG) Stock Fundamental Analysis
USA - NASDAQ:GLPG - US36315X1019 - ADR
31.96 USD
-0.07 (-0.22%)
31.96 USD
0 (0%)
GLPG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. The financial health of GLPG is average, but there are quite some concerns on its profitability. GLPG does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
GLPG had negative earnings in the past year.
In the past year GLPG has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.
GLPG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -7.45%, GLPG belongs to the best of the industry, outperforming 86.14% of the companies in the same industry.
GLPG's Return On Equity of -10.75% is amongst the best of the industry. GLPG outperforms 87.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.45% | ||
| ROE | -10.75% | ||
| ROIC | N/A |
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GLPG's Profit Margin has improved in the last couple of years.
GLPG's Gross Margin of 87.59% is amongst the best of the industry. GLPG outperforms 89.51% of its industry peers.
In the last couple of years the Gross Margin of GLPG has declined.
GLPG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLPG remains at a similar level compared to 1 year ago.
GLPG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GLPG has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.46, we must say that GLPG is in the distress zone and has some risk of bankruptcy.
GLPG has a Altman-Z score of 1.46. This is in the better half of the industry: GLPG outperforms 62.92% of its industry peers.
GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
GLPG's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. GLPG outperforms 47.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.46 |
ROIC/WACCN/A
WACC7.89%
2.3 Liquidity
A Current Ratio of 8.08 indicates that GLPG has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.08, GLPG is doing good in the industry, outperforming 73.60% of the companies in the same industry.
A Quick Ratio of 7.99 indicates that GLPG has no problem at all paying its short term obligations.
GLPG has a better Quick ratio (7.99) than 73.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.08 | ||
| Quick Ratio | 7.99 |
3. Growth
3.1 Past
GLPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -200.70%.
Measured over the past years, GLPG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -12.47% on average per year.
GLPG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -52.50%.
Measured over the past years, GLPG shows a very negative growth in Revenue. The Revenue has been decreasing by -20.82% on average per year.
EPS 1Y (TTM)-200.7%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-1242.86%
Revenue 1Y (TTM)-52.5%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%-16.16%
3.2 Future
Based on estimates for the next years, GLPG will show a very negative growth in Earnings Per Share. The EPS will decrease by -40.74% on average per year.
The Revenue is expected to decrease by -0.05% on average over the next years.
EPS Next Y-346.2%
EPS Next 2Y-84.1%
EPS Next 3Y-65.78%
EPS Next 5Y-40.74%
Revenue Next Year-5.39%
Revenue Next 2Y-2.52%
Revenue Next 3Y-4.07%
Revenue Next 5Y-0.05%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GLPG. In the last year negative earnings were reported.
Also next year GLPG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GLPG's earnings are expected to decrease with -65.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.1%
EPS Next 3Y-65.78%
5. Dividend
5.1 Amount
GLPG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.96
-0.07 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners25.23%
Inst Owner Change0.17%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap2.11B
Revenue(TTM)275.61M
Net Income(TTM)-284274000
Analysts48.24
Price Target35.19 (10.11%)
Short Float %3.37%
Short Ratio7.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1378.49%
Min EPS beat(2)-1682.53%
Max EPS beat(2)-1074.45%
EPS beat(4)1
Avg EPS beat(4)-663.96%
Min EPS beat(4)-1682.53%
Max EPS beat(4)154.1%
EPS beat(8)5
Avg EPS beat(8)-142.38%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.96%
Min Revenue beat(2)-10.27%
Max Revenue beat(2)4.35%
Revenue beat(4)1
Avg Revenue beat(4)-8.31%
Min Revenue beat(4)-15.5%
Max Revenue beat(4)4.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.04%
PT rev (3m)1.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)86.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-151.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.69 | ||
| P/tB | 0.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.03
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-5.25
FCFYN/A
OCF(TTM)-4.91
OCFYN/A
SpS4.86
BVpS46.59
TBVpS42.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.45% | ||
| ROE | -10.75% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.59% | ||
| FCFM | N/A |
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
F-Score1
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 30.4% | ||
| Cap/Sales | 7.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.08 | ||
| Quick Ratio | 7.99 | ||
| Altman-Z | 1.46 |
F-Score1
WACC7.89%
ROIC/WACCN/A
Cap/Depr(3y)93.66%
Cap/Depr(5y)187.37%
Cap/Sales(3y)17.05%
Cap/Sales(5y)15.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-200.7%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-1242.86%
EPS Next Y-346.2%
EPS Next 2Y-84.1%
EPS Next 3Y-65.78%
EPS Next 5Y-40.74%
Revenue 1Y (TTM)-52.5%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%-16.16%
Revenue Next Year-5.39%
Revenue Next 2Y-2.52%
Revenue Next 3Y-4.07%
Revenue Next 5Y-0.05%
EBIT growth 1Y-98.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.52%
EBIT Next 3Y-12.01%
EBIT Next 5Y14.78%
FCF growth 1Y45.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.13%
OCF growth 3YN/A
OCF growth 5YN/A
GALAPAGOS NV-SPON ADR / GLPG FAQ
What is the fundamental rating for GLPG stock?
ChartMill assigns a fundamental rating of 2 / 10 to GLPG.
What is the valuation status of GALAPAGOS NV-SPON ADR (GLPG) stock?
ChartMill assigns a valuation rating of 0 / 10 to GALAPAGOS NV-SPON ADR (GLPG). This can be considered as Overvalued.
What is the profitability of GLPG stock?
GALAPAGOS NV-SPON ADR (GLPG) has a profitability rating of 3 / 10.
What is the financial health of GALAPAGOS NV-SPON ADR (GLPG) stock?
The financial health rating of GALAPAGOS NV-SPON ADR (GLPG) is 4 / 10.